OppenheimerFunds’s Aratana Therapeutics, Inc. PETX Stock Holding History

OppenheimerFunds’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-580,343	Closed	-$3.24M	–	1759
2015 Q4	$3.24M	Buy	580,343 +34,774	+6%	+$230K	﹤0.01%	861
2015 Q3	$4.62M	Buy	545,569 +12,190	+2%	+$206K	0.01%	820
2015 Q2	$8.06M	Sell	533,379 -3,233	-0.6%	-$46.7K	0.01%	787
2015 Q1	$8.59M	Buy	536,612 +5,960	+1%	+$106K	0.01%	783
2014 Q4	$9.46M	Buy	530,652 +73,433	+16%	+$915K	0.01%	776
2014 Q3	$4.59M	Buy	457,219 +108,875	+31%	+$1.32M	0.01%	839
2014 Q2	$5.44M	Buy	348,344 +66,052	+23%	+$936K	0.01%	834
2014 Q1	$5.24M	Buy	282,292 +195,113	+224%	+$3.91M	0.01%	836
2013 Q4	$1.67M	Buy	+87,179	New	+$1.77M	﹤0.01%	870

Other funds holding PETX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

OppenheimerFunds's PETX Position: Q1 2016 in Review

OppenheimerFunds sold out of Aratana Therapeutics, Inc. (PETX) in Q1 2016, closing a stake of 580,343 shares — an estimated $3.24M sold.

OppenheimerFunds first reported a position in PETX in Q4 2013 and held it in 9 quarters. The position peaked at $9.46M in Q4 2014. 95 funds tracked by Wall St. Rank hold PETX as of Q1 2016.

OppenheimerFunds reported no remaining Aratana Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
OppenheimerFunds sold 580,343 Aratana Therapeutics, Inc. shares in Q1 2016, an estimated $3.24M.
OppenheimerFunds first reported a position in Aratana Therapeutics, Inc. in Q4 2013 and held it in 9 quarters.
OppenheimerFunds's Aratana Therapeutics, Inc. position peaked at $9.46M in Q4 2014.
95 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q1 2016.

Based on OppenheimerFunds's 13F filing for Q1 2016, filed 12 May 2016.